Table 1.

Characteristic of included studies in meta-analysis.

Author(s) & Year of Publication	Treatment Duration (Week(s))	Age (Mean years)	Attrition Percent	Isoflavone Dose (mg)	Protein	Type of Treatments	Type of Control Group	No. of patients in treatment groups	No. of patients in control groups	Randomization Technique	Blinding	Intention-to-treat reporting	Two groups were similar before the treatment
Baird et al., 1995	4	45-65	6%	165	No	Protein	Regular regimen	63	24	No	Yes	Yes	No
D’Anna et al., 2007	48	50-70		27	No	A tablet containing isoflavone supplement	placebo	198	191	Yes	Yes	Yes	Yes
Knight et al., 2001	12	53	16%	134	Yes	An isoflavone supplementation in the form of a powdered drink	Placebo	9	11	Yes	Yes	Yes	Yes
Radhakrishnan et al., 2009	24	53	15%	75	Yes	Soy Powder	Placebo	44	41	Yes	Yes	Yes	Yes
Chiechi et al., 2003	24	53	43%	47	Yes	Protein	Regular regimen	22	41	No	Yes	No	Yes
Levis et al., 2011	52 to 104	52	43%	200	No	Soy tablet	Placebo	81	71	Yes	Yes	Yes	Yes
Murkies et al., 1995	6 to 12	54	18%	Unidentified	No	Soy flour supplementation	Wheat flour	23	24	Yes	Yes	No	Yes
Carmignani et al., 2010	16	51	0	90	Yes	Soy Powder	Placebo	20 patients received conjugated estrogen & 20 patients received soy	20	Yes	Yes	Yes	Yes
Knight et al., 1999	12	51	5%	Low dose of 40 mgs / High dose of 160 mgs	-	Red clover	Placebo	13 patients in high-dose group  & 12 patients in low-dose group	12	Yes	Yes	No	Yes
Colli et al., 2012	24	53	17%	100 mgs of flaxseed lignan extract/ flaxseed bread/ 270 mgs of lignans	-	Flaxseed	Placebo	56 patients using flaxseed extract/ 54 patients using flaxseed bread	56	Yes	Yes	No	Yes